Levosimendan In Ambulatory Heart Failure Patients

NCT04705337 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-05-09

No results posted yet for this study

Summary

The objective of the study is to determine the efficacy of repeated infusions of levosimendan in the group of outpatients with advanced systolic heart failure (HF).

Conditions

  • Heart Failure New York Heart Association Class III
  • Heart Failure New York Heart Association Class IV
  • Heart Failure, Systolic
  • Heart Failure With Reduced Ejection Fraction

Interventions

DRUG

Levosimendan

administration of levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)

OTHER

Placebo

administration of glucose as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)

Sponsors & Collaborators

  • Medical Research Agency, Poland

    collaborator OTHER_GOV
  • University of Opole

    collaborator OTHER
  • Medical University of Lodz

    collaborator OTHER
  • Poznan University of Medical Sciences

    collaborator OTHER
  • Nicolaus Copernicus University

    collaborator OTHER
  • National Institute of Cardiology, Warsaw, Poland

    collaborator OTHER
  • Azienda Ospedaliera dei Colli

    collaborator OTHER
  • John Paul II Hospital, Krakow

    collaborator OTHER
  • Medical University of Bialystok

    lead OTHER

Principal Investigators

  • Agnieszka Tycińska, Prof. MD · Medical University of Bialystok

  • Marek Gierlotka, Prof. MD · University of Opole

  • Jarosław Kasprzak, Prof. MD · Medical University of Łódź

  • Jacek Kubica, Prof. MD · Nicolaus Copernicus University in Toruń

  • Grzegorz Grześk, Prof. MD · Nicolaus Copernicus University in Toruń

  • Jadwiga Nessler, Prof. MD · John Paul II Hospital, Krakow

  • Janina Stępińska, Prof. MD · Cardinal Stefan Wyszyński Institute of Cardiology

  • Ewa Straburzyńska-Migaj, Prof. MD · Poznan University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2024-02-29
Completion
2024-08-15

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04705337 on ClinicalTrials.gov